Anti-Rheumatics Market

Market Overview

The global anti-rheumatics market was valued at USD 62.8 billion in 2022. It is estimated to reach USD 79.82 billion by 2031, growing at a CAGR of 2.7% during the forecast period (2023–2031). It is anticipated that an increase in the older population would drive demand for implants used in managing orthopedic illnesses, which is likely to support the expansion of the market.

Anti-rheumatics is a category of drugs that are used to treat a variety of symptoms that are associated with rheumatoid arthritis. These drugs are effective in the treatment of a variety of conditions affecting the connective tissue, including systemic sclerosis (SSc), systematic lupus erythematosus (SLE), and Sjogren syndrome (SS). These drugs also effectively treat inflammatory myositis and intestinal illnesses, among the conditions that can be addressed. For administration into the body, they can be taken orally, injected subcutaneously (SC), or delivered intravenously (IV). They help reduce inflammation, which in turn helps prevent joint damage, reduce pain and swelling, and decrease the progression of arthritis. Rheumatologists, gastroenterologists, and dermatologists worldwide are increasingly considering anti-rheumatic medications as a potential course of treatment for their patients because of this.

Rheumatoid arthritis is an inflammatory arthritis that causes severe swelling and stiffness in the joints. It is the most common form of autoimmune arthritis. In addition to this, it has the potential to irritate the skin, the eyes, the lungs, the heart, and the blood vessels. As a consequence of this, the rising prevalence of this particular medical condition is one of the primary factors that is driving demand for anti-rheumatic drugs all over the world.

Market Dynamics

Global Anti-Rheumatics Market Drivers:

Surge in Geriatric Population Across the Globe

The constantly expanding population in their later years is one of the most important factors driving the market for anti-rheumatic medications. In recent years, there has been an increase in the prevalence of rheumatoid arthritis due to the tremendous rise in the world's population of older people. The information provided by RheumatoidArthritis.org indicates that a person in their 60s is the normal age at which they will begin to feel symptoms of rheumatoid arthritis. It is anticipated that an increase in the older population would drive demand for implants used in managing orthopedic illnesses, which is likely to support the expansion of the market. As a result of this, the market is expected to grow.

Rise in Prevalence of Rheumatoid Arthritis Across the Globe

Rheumatoid arthritis is a form of arthritis caused by an autoimmune disease. It produces pain and inflammation in the joints, making it difficult for a person to walk. As a consequence of this, the condition has grown to become a significant problem in every region of the world. In addition, the incidence of this disease is rising at a startlingly rapid rate over the entire planet. For instance, in the United Kingdom, rheumatoid arthritis affects 400,000 people, and osteoarthritis has been identified in 8.75 million people aged 45 and older.

In a manner parallel to this, the Australian Institute of Health and Welfare found that around 458,000 people living in Australia were affected with rheumatoid arthritis. The total population is represented by this number, which is 1.9%. As a direct consequence, the huge rise in the number of individuals with rheumatoid arthritis is one factor driving the expansion of the market.

Global Anti-Rheumatics Market Restraint:

Patent Expirations of Blockbuster Drugs

The introduction of low-cost generic alternatives after a patent has expired is one factor that inhibits the market's expansion. Furthermore, because biologics are seen as being essential for the treatment of rheumatoid arthritis, the market is currently saturated with a variety of different biologics. On the other hand, biologics are eroding their exclusivity, and several are on the point of having their patents expire. For example, Amgen Inc. could not maintain its patent exclusivity for Humira (adalimumab), although the company successfully extended its protection. As a result, generic versions of blockbuster pharmaceuticals are available when their respective patents expire. These generics affect the income generated in the market, which hinders the industry's expansion because of their low prices.

Global Anti-Rheumatics Market Opportunities:

High Growth Potential in Developing Economies

Anti-rheumatic drug manufacturers and distributors can capitalize on attractive expansion opportunities presented by developing economies worldwide. The ever-evolving life science industry is a primary factor in expanding the market in developing nations like India and China. Another element that contributes to the expansion of the market is the rising cost of medical care that is being experienced all over the world. Additionally, the expansion of the healthcare industry in economies that are still emerging is anticipated to contribute to the expansion of the market.

In addition, developing countries in Asia-Pacific and LAMEA have a big patient base for rheumatoid arthritis, which means that these countries have strong market potential. As a result, the variables mentioned above will, in the future, make available a great deal of potential for expanding the market.

Regional Analysis

North America Dominates the Global Market

The global anti-rheumatics market is bifurcated based on region into North America, Europe, Asia-Pacific, and LAMEA.

North America is the most significant global anti-rheumatics market shareholder and is estimated to exhibit a CAGR of 3.0% over the forecast period. Due to the rising frequency of rheumatoid arthritis in this region, North America held the greatest proportion of the worldwide anti-rheumatics market. For example, the Arthritis Society estimates that 300,000 Canadians have rheumatoid arthritis. As a result, there is an increase in demand for anti-rheumatics in the area due to the rising prevalence. Another important element driving the market for anti-rheumatics is the rise in the elderly population. Anti-rheumatic drug demand is, therefore, increased because older adults are more likely to develop rheumatoid arthritis.

Additionally, simple access to anti-rheumatic drugs and increased healthcare spending are anticipated to fuel market expansion in this area. Due to the rise in rheumatoid arthritis prevalence, North America held the greatest market share for anti-rheumatics. This trend is predicted to continue during the projected period. A major driver of the anti-rheumatics market's expansion is also the rise in the elderly population. Significant important companies like Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., AbbVie Inc., Pfizer, Inc., and Eli Lilly and Company are also driving the market for anti-rheumatics in the region.

Europe is anticipated to exhibit a CAGR of 2.4% over the forecast period. Europe held the second-largest proportion of the worldwide anti-rheumatics market because of factors like the presence of major players and broad knowledge of the effectiveness of these drugs in treating rheumatoid arthritis. In addition, a big senior population and a large patient base for rheumatoid arthritis are key factors that support the market's expansion. As a result, it is projected that the vast patient pool will raise demand for anti-rheumatic drugs, which are necessary to treat rheumatoid arthritis. Increased healthcare spending is one of the key elements driving market expansion in the area. The rise in rheumatoid arthritis prevalence, which increases demand for anti-rheumatics, is one of the causes driving the expansion of these medications in the area.

In Asia-Pacific, the anti-rheumatics market has plenty of attractive potential, which is also expected to develop at the fastest rate over the projected period. The countries in this region are densely populated, with China and India ranking first and second, respectively. Therefore, the Asia-Pacific anti-rheumatics market is anticipated to increase due to the region's ability to provide a sizable customer base. Rising healthcare costs and increased knowledge of anti-rheumatics use are also driving the market's expansion.

In addition, the rise in rheumatoid arthritis incidence in the area is another factor driving the market's expansion. The leading companies in the anti-rheumatics market may have opportunities due to a sizable prospective customer base and the rise in awareness of using anti-rheumatics for treating rheumatoid arthritis in Asia-Pacific. Additionally, a rise in healthcare spending in the area drives market expansion. Another significant factor driving the expansion of the anti-rheumatics market in Asia-Pacific is the region's rising prevalence of rheumatoid arthritis.

In LAMEA, the anti-rheumatics market is in its infancy due to low purchasing power, shortage of advanced healthcare facilities, inadequate health expenditure, and inadequate health coverage. The Brazilian healthcare system consists of a large public component, a small paid health insurance component, and a small private component in which consumers pay for medical services out of pocket. This hinders the development of anti-rheumatics in this region.

However, governments of various LAMEA nations have increased spending in the healthcare sector to entice key actors to expand their operations in the region. In addition, an increase in the prevalence of rheumatoid arthritis in the region leads to a rise in demand for faster healthcare services, which drives the market's expansion. LAMEA is an emerging market because healthcare expenditures are anticipated to increase during the forecast period, generating lucrative growth opportunities for market participants. A high prevalence of rheumatoid arthritis is another significant factor contributing to expanding the market in this region.

Segmental Analysis

The global anti-rheumatics market is bifurcated into drug class and type.

Based on the drug class, the global anti-rheumatics market is bifurcated into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs, and others. 

The disease-modifying anti-rheumatic drugs segment dominates the global market and is projected to exhibit a CAGR of 2.9% over the forecast period. Rheumatoid arthritis progression can be slowed down with the help of disease-modifying anti-rheumatic drugs (DMARDs). For instance, DMARDs can delay the progression of rheumatoid arthritis, resulting in fewer symptoms and less joint damage. Furthermore, there are two types of DMARDs on the market: conventional and biologics. Methotrexate and hydroxychloroquine are two further examples of conventional DMARDs. Enbrel and Humira are two biological medications that can be purchased to treat rheumatoid arthritis.

Additionally, biologics target specific immune proteins known as cytokines, while conventional DMARDs inhibit the immune system generally. The rise in awareness of the use of anti-rheumatics for the treatment of rheumatoid arthritis and the rise in the prevalence of the disease are the two main reasons contributing to the market's expansion. The industry is also being driven by the global increase in healthcare spending and the growth of the elderly population. The market is growing due to the extra advantages DMARDs provide, such as slowing the progression of arthritis.

Based on type, the global anti-rheumatics market is segmented into prescription-based drugs and over-the-counter drugs. 

The prescription-based drugs segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 2.8% over the forecast period. To supply a substance requiring a prescription, you must legally have a valid medical prescription. These are useful because they ensure that patients undergoing treatment for rheumatoid arthritis receive the appropriate dose of the drug without causing a significantly increased number of unwanted effects. This is why they are helpful. The most frequently recommended medications to patients are uric acid drugs and disease-modifying anti-rheumatic drugs, or DMARDs for short. Other anti-rheumatic treatments include Humira (adalimumab), Enbrel (etanercept), and Cimzia (certolizumab pegol), and each of these drugs is only available with a prescription from a medical professional.

Recent Developments

• January 2023- the DSI (Department of Science and Innovation) and IPASA (Innovative Pharmaceutical Association of South Spain) collaborated with the SAMRC (South Spain Medical Research Council) to enhance the R&D capability in South Spain along with the commercialization of novel and innovative health solutions and boosting the pharmaceutical sector in the country. The IPASA is an association comprising key market players like Merck, Novartis, Pfizer, and Roche, to name a few.

• June 2022- Cipla and DNDI launched child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa. The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable '4-in-1' fixed-dose combination of four antiretroviral (ARV) medications made up of abacavir, lamivudine, lopinavir, and ritonavir for infants and young children with HIV. Cipla Limited and the not-for-profit Drugs for Neglected Diseases initiative (DNDi) designed this combination medicine.